Mr. de la Huerga has an extensive in MedTech, as an executive leader of a startup. This company profitably grew eventually going public for $500 Million and that GE Healthcare subsequently purchased for $1 Billion. he has been involved in patient safety products for over 20 years, created a product line to save 5,000 patient lives a year that became an international standard and became a new $1 Billion market opportunity. He also has turned around 3 under-performing companies and divisions.

As Vice President of engineering he has built world leading development teams that grew companies through continuous innovation. He has experience working on FDA Class I, II, and III medical devices including defibrillators and infusion pump systems. He worked closely with physicians, nurses, and pharmacist to design and develop new medical products that 65% of healthcare givers rely on every day.

He has been an sponsored investigator/developer for an NIH contract. NIH contracts are rare and used when the NIH determines commercial vendors are not meeting a pressing clinical need. It is their subtle way to influence the market. This contract allowed a top level team to develop new medication administration products to prevent and detect the misuse of controlled substances by healthcare givers in hospitals and to keep patients safe.

He has been a business leader with proven track record of delivering multiple generations of new healthcare products and services (multi-$billion) that have saved lives and prevented injuries by increasing diagnostic and treatment accuracy/safety while reducing costs. He has had P&L responsibility for large business divisions and for startups. He has worked with small teams from 1 to 6 and with teams working in major Fortune companies - each to developer essential solutions to pressing healthcare problems. Often the best developments were the result of the smallest and most dedicated teams.

His prior work in patient safety systems developed of a new IV medication safety system and international standard that saved 5,000 lives a year. He has 33 prior patents.

He has an extensive background in medical devices, healthcare data collection systems, information technology, and caregiver workflow.

Michael Millard is the CEO of Medication Consultation Services, providing guidance to the pharmacy community and to governmental bodies regarding pharmacy practice. He was a Professor of Pharmacy at Pacific University School of Pharmacy, with a teaching and research focus on Pharmacy Law and Leadership. He was a contractor on the NIH contract awarded and completed on developing new drug diversion prevention software and hardware in the healthcare setting.

He has 35 years of experience in hospital pharmacy management of large health-systems. He has seen the catastrophic effect of drug addiction on health care providers and patients. I have a life-long interest in preventing and limiting opioid use disorders, especially in the healthcare setting. My years of teaching nurses the therapeutics of drugs and their proper use has educated me to the unique role and function nurses play in the administration of controlled substances to patients. During my 12 years of service on the Prescription Drug Monitoring Program Advisory Board I have seen a decline in unintended death due to prescribed opioids but with no decrease in healthcare provider misuse.

Dr. Boortz-Marx's backgrround is remarkably unique. He has a nursing degree, worked in the critical care environment, and for two years he then became a professor of nursing. Giving him an understanding of the challenges and temptations nurses encounter when administering medications.

He then went to medical school trained as an anesthesiologist with a subspecialty in pain medicine. His career included eight years as Director of Interventional Pain Medicine, Department of Anesthesiology, Duke University School of Medicine. During that time he had to deal with many issues that affected nurses, physicians, and patients.

He has also been a consultant to the FBl regarding the theft pain medications in hospitals. These were often involved individuals who were least the suspect and often quite surprising once identified.

He is curently the head of Global Pain Consultants of North Carolina, a clinical trials, research, and education-based consulting company

Robert Strongin, PhD is a Professor of Chemistry at Portland State University and an Adjunct Professor of Physiology and Pharmacology at the Oregon Health and Science University. Besides academic research he has also worked as a chemist at SmithKline Beecham. He has trained in the fields of organic synthesis and physical organic chemistry. He has been an NIH supported research scientist and has been the Chair of several NIH study section to review grants submitted to the NIH.

He has been responsible for the evaluation of the chemical properties of existing controlled substance “wasting" chemicals and the development and analysis of various chemical structure to render controlled substances to be non-retrievable to meet the DEA requirements. He has a DEA license to order, possess, and conduct experiments with controlled substances.

His laboratory is fully equipped with analytic chemistry instrumentation and has access to additional chemical analysis and experimental equipment at Portland State University.

His bibliography of published research can be found at NCBI at the NIH